Boswellia serrata was associated with acute kidney injury during radiation necrosis treatment
A case report linked high-dose Boswellia serrata use for radiation necrosis with reversible acute kidney injury.
Tag
toxicity
Thyroid complication models showed only moderate long-term validation in head and neck cancer
Existing thyroid complication models showed moderate performance and frequent miscalibration in long-term head and neck cancer survivorship.
Computed tomography radiomics showed exploratory recurrence signals in mandibular osteoradionecrosis
In 24 surgically confirmed cases, three radiomic features differed nominally between pure osteoradionecrosis and osteoradionecrosis with recurrence.
Preoperative radiotherapy did not worsen renal function after retroperitoneal sarcoma surgery
Preoperative radiotherapy was not associated with greater renal dysfunction after nephrectomy for retroperitoneal sarcoma during follow-up extending to 80 months.
Early diffusion changes precede brain lesions after proton therapy for low-grade glioma
Regional diffusion changes distinguished patients who developed contrast-enhancing brain lesions as early as six months after proton therapy.
Body composition adds little to radiotherapy toxicity prediction
Computed tomography-derived muscle measures ranked highly for toxicity and quality of life, but added little predictive value beyond established clinical factors.
Glutathione S-transferase mu 3 limits testicular injury after ultrahigh dose-rate irradiation
In mice, ultrahigh dose-rate X-rays caused less early testicular damage than conventional irradiation, with protection linked to ferroptosis suppression.
Ultrahigh dose-rate radiotherapy still requires conformal planning and conservative dose constraints
Normal-tissue sparing with ultrahigh dose-rate radiotherapy remains conditional and cannot replace conformal dosimetry, organ-at-risk constraints, or rigorous quality assurance.
Risk-adapted esophagus sparing reduces dose with low severe esophagitis in lung cancer
Risk-adapted esophagus-sparing radiotherapy maintained target coverage, with grade 3 esophagitis in only 1.25% of high-risk patients.
Bone marrow-sparing radiotherapy lowers pelvic marrow dose without proven toxicity reduction
Bone marrow-sparing planning reduced pelvic marrow dose, but heterogeneous evidence did not confirm a consistent reduction in hematologic toxicity.
Brain radiotherapy alone did not deplete circulating lymphocytes in a prospective cohort
Circulating lymphocyte counts remained stable during brain radiotherapy without concurrent chemotherapy, consistent with low estimated blood and cervical lymph-node dose